Single-cell transcriptomic and epigenomic profiling of acute myeloid leukemia before and after venetoclax-decitabine therapy
Acute myeloid leukemia (AML) is a heterogeneous hematologic malignancy with variable responses to venetoclax-decitabine (VEN-DEC) therapy. To investigate molecular mechanisms associated with treatment response and resistance, we generated single-cell transcriptomic and epigenomic datasets from paired AML patient samples collected before and after VEN-DEC treatment in a prospective clinical trial (NCT03404193). The dataset includes single-cell RNA sequencing profiles from peripheral blood and bone marrow mononuclear cells representing multiple treatment-response groups. These data provide a resource for investigating leukemia cell heterogeneity, stem-like cell populations, treatment-associated transcriptional changes, and mechanisms of therapeutic resistance.
BioProject